Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Brooke Bond Black Tea Extract on Flow Mediated Dilation in Indian Males

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01561300
Recruitment Status : Completed
First Posted : March 23, 2012
Results First Posted : April 5, 2017
Last Update Posted : April 5, 2017
Sponsor:
Collaborators:
Lotus Labs Pvt. Ltd, Bangalore, India
Clumax Diagnostics, Bangalore, India
Quipu S.r.l, Pisa, Italy
Information provided by (Responsible Party):
Unilever R&D

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study examines the effect of 1800 mg/day standardized Brooke Bond black tea extract, equivalent to 400 mg flavonoids, on Flow Mediated Dilation in healthy Indian males.

Condition or disease Intervention/treatment Phase
Healthy Other: Nutrition intervention study with a black tea extract Other: Nutrition intervention study with a control Not Applicable

Detailed Description:
Flow mediated dilation (FMD) is a non-invasive measurement technique performed using ultrasound equipment to measure hyperaemia induced dilation of blood vessels. Evidence from prospective studies suggests that FMD is independently inversely associated with cardiovascular events.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: Efficacy of Standardized Brooke Bond Black Tea Extract on Flow-Mediated Dilation After an Acute Dose as Well as After One Week of Consumption in Healthy Adult Indian Males
Study Start Date : March 2012
Actual Primary Completion Date : April 2012
Actual Study Completion Date : May 2012

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Placebo Comparator: Control
Nutrition intervention study with a control
 Other: Nutrition intervention study with a control

Control: 1800 mg/day of a powder that gives a flavoured beverage with a color similar to black tea dissolved in 240 ml hot water.

Products will be consumed for 8 days. On measurement days control will be given to the subjects as a single acute dose and 2 grams of sugar will be added.

On day 2-7 subjects will consume 3 cups of control, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added.

Other Name: Control
Experimental: Tea extract
Nutrition intervention study with a black tea extract
 Other: Nutrition intervention study with a black tea extract

Tea extract: 1800 mg/day standardized Brooke Bond black tea extract equivalent to 400 mg flavonoids dissolved in 240 ml hot water.

Products will be consumed for 8 days. On measurement days tea will be given to the subjects as a single acute dose and 2 grams of sugar will be added.

On day 2-7 subjects will consume 3 cups or tea, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added.

Other Name: Black tea extract


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. 'Acute-upon-chronic Effect' of Tea vs Control [ Time Frame: Baseline day 1 to 2 hours post consumption on day 8. ]

    Change in flow mediated dilation (FMD) due to tea consumption when compared to control.

    FMD measurement included the following steps:

    • 1 minute base scan to measure the baseline diameter of artery (baseline)
    • 5 minutes of forearm occlusion at 300±30 mmHg, just below the elbow 2-5 cm from antecubital crease
    • 4 minutes FMD scan, which started immediately after release of the occlusion (reactive hyperaemia stage) FMD was calculated as maximal percentage change in diameter of the artery above the baseline value after the release of the occlusion


Secondary Outcome Measures :
  1. Acute Effect of Tea vs Control [ Time Frame: From baseline on day 1 to 2 hours post consumption on day 1 ]

    Change in flow mediated dilation due to tea consumption when compared to control.

    FMD measurement included the following steps:

    • 1 minute base scan to measure the baseline diameter of artery (baseline)
    • 5 minutes of forearm occlusion at 300±30 mmHg, just below the elbow 2-5 cm from antecubital crease
    • 4 minutes FMD scan, which started immediately after release of the occlusion (reactive hyperaemia stage) FMD was calculated as maximal percentage change in diameter of the artery above the baseline value after the release of the occlusion

  2. Chronic Effect of Tea vs Control [ Time Frame: From baseline at day 1 to baseline on day 8 ]

    Change in flow mediated dilation (FMD) due to tea consumption when compared to control.

    FMD measurement included the following steps:

    • 1 minute base scan to measure the baseline diameter of artery (baseline)
    • 5 minutes of forearm occlusion at 300±30 mmHg, just below the elbow 2-5 cm from antecubital crease
    • 4 minutes FMD scan, which started immediately after release of the occlusion (reactive hyperaemia stage) FMD was calculated as maximal percentage change in diameter of the artery above the baseline value after the release of the occlusion


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male volunteers aged between >_30 _< 50 years of age
  • Body Mass Index (BMI) of >_18 and _< 25.0 kg/m2
  • Systolic blood pressure >_140 and >_100 mmHg and diastolic blood pressure < 90 and > 70 mmHg
  • Subjects who consume _< 2 cups of coffee per day
  • Subjects who drink tea regularly (>_ 2 cups per day)
  • Apparently healthy, with no reported medical condition which might affect the assessment as judged by the study physician or/and PI
  • No prescribed medical treatment that may affect study parameters as judged by the Study Physician
  • Subject willing to abstain from alcohol on day before and on the day of assessment
  • Willing to sign the informed consent form

Exclusion Criteria:

  • Smokers and/or tobacco chewers
  • Those who consume regular alcohol (> 160 ml of alcohol per week)
  • Reported intense sport activities > 10h/week
  • Participating in any other clinical study concurrently or if participated in any study during 2 months preceding the screening visit
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01561300


Locations
Layout table for location information
India
Lotus Labs Pvt. Ltd.,
Bangalore, Karnataka, India, 560011
Sponsors and Collaborators
Unilever R&D
Lotus Labs Pvt. Ltd, Bangalore, India
Clumax Diagnostics, Bangalore, India
Quipu S.r.l, Pisa, Italy
Investigators
Layout table for investigator information
Study Director: Anisha Pargal, Dr Unilever Industries Pvt. Ltd
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Unilever R&D
ClinicalTrials.gov Identifier: NCT01561300    
Other Study ID Numbers: FDS-BEV-0284
First Posted: March 23, 2012    Key Record Dates
Results First Posted: April 5, 2017
Last Update Posted: April 5, 2017
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Unilever R&D:
Black tea
Flow Mediated Dilation
Vascular function
India
Additional relevant MeSH terms:
Layout table for MeSH terms
Dilatation, Pathologic
Pathological Conditions, Anatomical